Target intelligence / Profile preview

Mediator complex subunit 17 (MED17)

Target
MED17
Molecular classification
Transcription coactivator, Component of the Mediator complex, Structural scaffold (within the complex), Other
01

Overview

Mediator complex subunit 17 (MED17) is a critical structural and functional component of the Mediator complex—a large multi-protein assembly that acts as a central coactivator for regulated transcription of almost all RNA polymerase II-dependent genes in eukaryotes[1][2][3][4]. MED17 forms the main connection between the head and other modules of the Mediator, functioning as a scaffold for assembly and recruitment of additional subunits and transcription factors[3][4][5]. Its activity is essential for transcription initiation, and it mediates interactions with SP1, nuclear hormone receptors (like thyroid hormone and vitamin D receptors), and DNA repair machinery (linking it to nucleotide excision repair processes)[2][6]. Loss or mutation of MED17 leads to profound gene expression defects and is associated with rare neurodevelopmental disease in humans[1]. Currently, no drugs directly target MED17, and experimental evidence suggests that perturbing its function results in broad deleterious cellular effects[1][6].

Other names
Mediator of RNA polymerase II transcription subunit 17ARC77CRSP6DRIP77DRIP80TRAP80CRSP complex subunit 6Trap80CRSP77SRB4Cofactor required for Sp1 transcriptional activation subunit 6Thyroid hormone receptor-associated protein complex 80 kDa componentTranscriptional coactivator CRSP77Vitamin D3 receptor-interacting protein complex 80 kDa componentEpididymis secretory sperm binding protein (rare/obsolete)
02

Mechanism of action

Not applicable; no direct drugs/mechanism targeting MED17. Any pharmacological effect would be indirect or via broader disruption of transcriptional machinery or the Mediator complex.

03

Biological functions

Regulation of transcription by RNA polymerase IIMediator complex assembly and structural scaffoldTranscriptional activation in response to specific transcription factors (e.g., SP1, nuclear hormone receptors)Bridging regulatory signals to the general transcription machineryNuclear receptor coactivation (e.g., thyroid hormone, vitamin D receptors)Switching between transcription and DNA repair (NER)
04

Disease associations

Neurodevelopmental disorders: Microcephaly, postnatal progressive, with seizures and brain atrophy; Non-syndromic pontocerebellar hypoplasiaSome connection to cancer/dna repair machinery via interaction with BRCA1, p53, and NER proteins (studied, but not a classical drug target)Other
05

Safety considerations

Not directly applicable; knockdown, mutation, or dysfunction of MED17 results in widespread transcriptional defects and severe multi-system consequences (e.g., neurodevelopmental disorders), suggesting targeting MED17 would likely have global deleterious effects rather than therapeutic benefitEssential for viability in model organisms
06

Interacting drugs

None documented as of now; no approved drugs directly target MED17
07

Biomarkers

None currently established for patient selection or efficacy monitoring through MED17 specifically

Beyond the preview

Go deeper on Mediator complex subunit 17 (MED17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediator complex subunit 17 (MED17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call